Home › Calculator › IPHYF Dividend Calculator 2026
IPHYF Dividend DRIP Calculator 2026
121.21% YieldHealthcareInnate Pharma S.A. · OTC
Price: $1.65 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When IPHYF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your IPHYF snowball 📈
$10,000 in IPHYF → $5006678710805.47M in 10 years · $416,887,354,740,630,600.00/month
About Innate Pharma S.A. (IPHYF) — Dividend Analysis 2026
Innate Pharma S.A., a biotechnology firm based in Marseille, France, operates globally, focusing on the discovery, advancement, and commercialization of innovative antibody-based therapies, primarily targeting various oncological conditions. The company's clinical pipeline includes several promising candidates: Lacutamab (IPH4102): An anti-KIR3DL2 antibody currently undergoing Phase II clinical evaluation for cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor that has progressed to Phase III clinical trials, being investigated for its potential in treating advanced solid tumors, notably colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal antibody designed to block C5a binding to C5aR1. This compound is in Phase II clinical assessment for a range of inflammatory conditions, including COVID-19, bullous pemphigoid, and chronic spontaneous urticaria. IPH5201: A blocking antibody in Phase I trials, aimed at the CD39 immunosuppressive pathway. IPH5301: An anti-CD73 antibody targeting the immunosuppressive adenosine pathway to enhance anti-tumor immunity. IPH6101: An NKp46-based NK cell engager, intended for the development and assessment of up to two bispecific NK cell engagers. Beyond its clinical programs, Innate Pharma maintains an active preclinical research effort, featuring candidates such as IPH43 (an anti-MICA/B antibody-drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), and the IPH62 and IPH64 programs. To support its development and market reach, Innate Pharma has established strategic alliances and licensing agreements with major pharmaceutical companies, including AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Additionally, it holds a co-development and license agreement with MedImmune Limited. The company was founded in 1999 and continues to operate from its headquarters in Marseille, France.
Compare IPHYF with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full IPHYF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open IPHYF position with:
🌍 IPHYF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold IPHYF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 121.21% | 118.41% | $12,121 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 103.03% | 100.23% | $10,303 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 96.97% | 94.17% | $9,697 / yr |
| 🇬🇧 UK ISA | 0% | 121.21% | 118.41% | $12,121 / yr |
| 🇬🇧 UK Taxable | 8.75% | 110.60% | 107.80% | $11,060 / yr |
| 🇨🇦 TFSA | 0% | 121.21% | 118.41% | $12,121 / yr |
| 🇨🇦 CA Taxable | 25% | 90.91% | 88.11% | $9,091 / yr |
| 🇦🇺 Super (pension) | 15% | 103.03% | 100.23% | $10,303 / yr |
| 🇦🇺 AU Taxable | 30% | 84.85% | 82.05% | $8,485 / yr |
| 🇩🇪 DE Taxable | 26.375% | 89.24% | 86.44% | $8,924 / yr |
| 🇫🇷 FR Taxable | 30% | 84.85% | 82.05% | $8,485 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 IPHYF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 IPHYF Dividend Payment Schedule
IPHYF pays quarterly — 4 times per year. Next ex-div: TBD.
📊 IPHYF vs Healthcare Benchmarks
How IPHYF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for IPHYF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ IPHYF Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the IPHYF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Innate Pharma S.A. (IPHYF) is currently trading at $1.65, 73% below its 52-week high. The current dividend yield is 121.21% based on an annual payout of $2.00 per share.
IPHYF (Innate Pharma S.A.) — 121.21% Dividend Yield Analysis
Innate Pharma S.A. (IPHYF) is a healthcare stock currently trading at $1.65 with a dividend yield of 121.21%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (121.21%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest IPHYF News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.